New hope for hospital patients: drug may shield kidneys from harmful meds
NCT ID NCT06886464
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether cilastatin, a drug already used for other purposes, can prevent acute kidney injury in hospitalized patients who must take medications known to harm the kidneys. About 700 adults receiving certain antibiotics, chemotherapy, or contrast dyes will receive either cilastatin or a placebo every six hours. Researchers will monitor kidney function daily and follow up at 90 days to see if the drug reduces kidney damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Alberta
RECRUITINGEdmonton, Alberta, T6G 2R3, Canada
-
University of Calgary
RECRUITINGCalgary, Alberta, T2N 1N4, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which emergency dialysis saves more lives? a new study investigates
- A simple sensor on the back could warn of kidney danger during heart surgery
- Can a common blood thinner be safe for ICU patients with liver issues?
- A urine test that could foresee kidney danger in the ICU
- Which citrate solution minimizes metabolic chaos in kidney therapy?
- A wearable sensor might spot kidney danger before it strikes